Portal de Periódicos da CAPES

Isradipine—A Review of Its Antihypertensive and Other Properties

1992; Wiley; Volume: 10; Issue: 1 Linguagem: Inglês

10.1111/j.1527-3466.1992.tb00234.x

1527-3466

DavidG. Holmes, Robert P. Hof, P. Rüegg, H. Schön,

Pharmacology and Obesity Treatment

Cardiovascular Drug ReviewsVolume 10, Issue 1 p. 3-25 Free to Read Isradipine—A Review of Its Antihypertensive and Other Properties D. Holmes, Corresponding Author D. Holmes Sandoz Pharma Ltd., Basel, SwitzerlandAddress correspondence and reprint requests to Dr. D. Holmes, at Clinical Research Dept., Sandoz Pharma Ltd., CH 4002 Basel, Switzerland.Search for more papers by this authorR. P. Hof, R. P. Hof Sandoz Pharma Ltd., Basel, SwitzerlandSearch for more papers by this authorP. C. Rüegg, P. C. Rüegg Sandoz Pharma Ltd., Basel, SwitzerlandSearch for more papers by this authorH. Schön, H. Schön Sandoz Pharma Ltd., Basel, SwitzerlandSearch for more papers by this author D. Holmes, Corresponding Author D. Holmes Sandoz Pharma Ltd., Basel, SwitzerlandAddress correspondence and reprint requests to Dr. D. Holmes, at Clinical Research Dept., Sandoz Pharma Ltd., CH 4002 Basel, Switzerland.Search for more papers by this authorR. P. Hof, R. P. Hof Sandoz Pharma Ltd., Basel, SwitzerlandSearch for more papers by this authorP. C. Rüegg, P. C. Rüegg Sandoz Pharma Ltd., Basel, SwitzerlandSearch for more papers by this authorH. Schön, H. Schön Sandoz Pharma Ltd., Basel, SwitzerlandSearch for more papers by this author First published: March 1992 https://doi.org/10.1111/j.1527-3466.1992.tb00234.xCitations: 2AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Afonso S, O'Brien GS. Mechanism of enhancement of adenosine action by dipyridamole and lidoflazine in dogs. Arch Int Pharmacodyn Ther 1971; 194: 181– 96. 2 Albarquez RF Jr, Cabral EI, Namin EP, et al. Isradipine dose confirmation study in Filipino patients with mild to moderate hypertension. Drugs 1990; 40(suppl 2): 33– 7. 3 Ames RP. Negative effects of diuretic drugs on metabolic risk factors for coronary heart disease: possible alternative drug therapies. Am J Cardiol 1983; 51: 632– 8. 4 Applegate WB, Byington RP. MIDAS, the Multicenter Isradipine-Diuretic Atherosclerosis Study. Design features and baseline data. Am J Hypertens 1991; 4(suppl): 114S– 7. 5 Bedotto JB, Eichhorn EJ, Popma JJ, Dehmer GJ. Effects of intravenous isradipine on left ventricular performance during rapid atrial pacing in coronary heart disease. Am J Cardiol 1990; 65: 189– 94. 6 Berg KJ, Holdaas H, Endresen L, et al. Effects of isradipine on renal function in cyclosporin-treated renal transplanted patients. Nephrol Dial Transplant 1991; 6: 725– 30. 7 Bond MG, Strickland HL, Wilmoth SK, Safrit A, Phillips R, Szostak L, for the MIDAS Research Group. Interventional clinical trials using noninvasive ultrasound end points: the Multicenter Isradipine-Diuretic Atherosclerosis Study. J Cardiovasc Pharmacol 1990; 15(suppl 1): S30– 3. 8 Borsotto M, Barhanin J, Norman RI, Lazdunski M. Purification of the dihydropyridine receptor of the voltage dependent Ca2+ channel from skeletal muscle transverse tubules using (+)[3H]PN200–110. Biochem Biophys Res Commun 1984; 122: 1357– 66. 9 Bossert F, Vater W. Dihydropyridine, eine neue Gruppe stark wirksamer Coronartherapeutika. Naturwissenschaften 1971; 58: 578. 10 Boström ST, Ljung B, Mårdh S, Forsen S, Thulin E. Interaction of the antihypertensive drug felodipine with calmodulin. Nature (Lond) 1981; 292: 777– 8. 11 Boyd RA, Giacomini JC, Giacomini KM. Species differences in the negative inotropic response of 1,4-dihydropyridine calcium channel blockers in myocardium. J Cardiovasc Pharmacol 1988; 12: 650– 7. 12 Blister NW, Bamette RE, Schartel SA, McClurken JB, Alpera J. Isradipine for treatment of acute hypertension after myocardial revascularisation. Crit Care Med 1991; 19: 334– 8. 13 The British Isradipine Hypertension Group. Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. Am J Med 1989; 86(suppl 4A): 110– 4. 14 Castensen MH, Bahnsen J, Sterzing E. Tocolysis with beta-sympathomimetics alone or combined with the calcium antagonist verapamil. Geburtshitfe Frauenheilkd 1983; 7: 431– 7. 15 Cauvin C, Loutzenhiser R, Van Breemen C. Mechanisms of calcium antagonist-induced vasodilation. Annu Rev Pharmacol Toxicol 1983; 23: 373– 96. 16 Chandler MHH, Schran HF, Cutler RE, Smith AJ, Gonasun LM, Blouin RA. The effects of renal function of the disposition of isradipine. J Clin Pharmacol 1988; 28: 1076– 80. 17 Christensen HR, Kampmann JP, Simonsen K. A randomized comparison of isradipine slow release given once daily with isradipine twice daily on 24 hour blood pressure in hypertensive patients. J Hum Hypertens 1991; 5: 121– 7. 18 Churchill PC. Second messengers in renin secretion. Am J Physiol 1985; 249: F175– 84. 19 Clifton GD, Blouin RA, Dilea C, et al. The pharmacokinetics of oral isradipine in normal volunteers. J Clin Pharmacol 1988; 28: 36– 42. 20 Cook NS, Hof RP. Cardioprotection by the calcium antagonist PN200–110 in the absence and presence of cardiodepression. Br J Pharmacol 1985; 86: 181– 9. 21 Cotting J, Reichen J, Kutz K, Laplanche R, Nüesch E. Pharmacokinetics of isradipine in patients with chronic liver disease. Eur J Clin Pharmacol 1990; 38: 599– 603. 22 Craven PA, DeRubertis FR. Ca2+ -dependent modulation of renin release from isolated glomeruli: apparent independence from alterations in cGMP. Metabolism 1985; 34: 651– 7. 23 Dacquet C, Loirand G, Rakotoarisoa L, Mironneau C, Mironneau J. (+)-[3H]-PN 200–110 binding to cell membranes and intact strips of portal vein smooth muscle: characterization and modulation by membrane potential and divalent cations. Br J Pharmacol 1989; 97: 256– 62. 24 The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II—DAVIT II). Am J Cardiol 1990; 66: 779– 85. 25 Defeudis FV. Further promiscuity of phenylalkylamine Ca2+ antagonists. Trends Pharmacol Sci 1988; 9: 352– 3. 26 De Keyser P, Bouvé J, Clement D, et al. Isradipine in essential hypertension: the Belgian General Practitioners' Study. Am J Med 1989; 86(suppl 4A): 103– 9. 27 Diemont WL, Stegeman CJ, Beekmann J, Siegers AMJ, Hagels G, de Bruijn JHB. Low-dose isradipine once daily effectively controls 24-h blood pressure in essential hypertension. Am J Hypertens 1991; 4(suppl): 163S– 7. 28 Eisner GM, Johnson BF, McMahon FG, et al. A multicentre comparison of the safety and efficacy of isradipine and enalapril in the treatment of hypertension. Am J Hypertens 1991; 4(suppl): 154S– 7. 29 Estefanous FG, Tarazi RC. Systemic arterial hypertension associated with cardiac surgery. Am J Cardiol 1980; 46: 685– 94. 30 Ferry DR, Glossmann H. Identification of putative calcium channels in skeletal muscle microsomes. FEBS Lett 1982; 148: 331– 7. 31 Fet̆kovská N, Fedelešová V, Dzúrik R. Low-density lipoprotein amplifies the platelet response to serotonin in human plasma. J Hypertens 1989; 7(suppl 6): S164– 5. 32 Fet̆kovská N, Fedelešová V, Kozlovsky M, Dzúrik R. Platelet-activating effect of low-density lipoprotein and its reversal by isradipine. Am J Hypertens 1991; 4(suppl): 175S– 7. 33 Fitscha P, Virgolini I, Rauscha F, Sinzinger H. Effects of isradipine on platelet function in hypertension at rest and during exercise. Am J Hypertens 1991; 4(suppl): 178S– 80. 34 Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1977; 17: 149– 66. 35 Fleckenstein A, Frey M, Zorn J, Fleckenstein-Gruen G. Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists. Am J Cardiol 1985; 56: 3– 14. 36 Furberg C, Byington RP, Borhani NA, and The Midas Research Group. Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). Design features. Am J Med 1989; 86(suppl 4A): 37– 9. 37 Gähwiler BH, Brown DA. Effects of dihydropyridines on calcium currents in CA3 pyramidal cells in slice cultures of rat hippocampus. Neuroscience 1987; 20: 731– 8. 38 Galizzi JP, Borsotto M, Barhanin J, Fosset M, Lazdunski M. Characterization and photoaffinity labeling of receptor sites for the Ca2+ channel inhibitors d-cis-diltiazem, (±)bepridil, desmethoxyverapamil, and (+)PN200–110 in skeletal muscle transverse tubule membranes. J Biol Chem 1986; 261: 1393– 7. 39 Gleerup G, Winther K. Decreased fibrinolytic activity and increased platelet function in hypertension. Am J Hypertens 1991; 4(suppl): 168S– 71. 40 Glossmann H, Ferry DR, Goll A, Rombush M. Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium channel label, [125I]iodipine. J Cardiovasc Pharmacol 1984; 6(suppl 4): S608– 21. 41 Godfraind T, Morel N, Wibo M. Tissue specificity of dihydropyridine-type calcium antagonists in human isolated tissues. Trends Pharmacol Sci 1988; 9: 37– 9. 42 Griebenow R, Kaufmann W, Krämer L, et al. Isradipine: a new calcium antagonist with strong vasodilatory but negligible cardiodepressive effects. J Cardiovasc Pharmacol 1990; 15(suppl 1): S84– 6. 43 Grundy SM, Lena Vega G. Role of apolipoprotein levels in clinical practice. Arch Intern Med 1990; 150: 1579– 81. 44 Habib JB, Bossaller C, Wells S, Williams C, Morrisett JD, Henry PD. Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN200–110. Circ Res 1986; 58: 305– 9. 45 Handley DA, VanValen RG, Melden MK, Saunders RN. Suppression of rat carotid lesion development by the calcium channel blocker PN200–110. Am J Pathol 1986; 124: 88– 93. 46 Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol 1980; 46: 1047– 58. 47 Henry PD. Calcium antagonists as antiatherogenic agents. Ann NY Acad Sci 1988; 522: 411– 9. 48 Henry PD. Calcium channel blockers and atherosclerosis. J Cardiovasc Pharmacol 1990; 16(suppl 1): S12– 5. 49 Hof RP. Pharmacological characterization of calcium antagonists: what they do and where they act. Triangle 1985; 24: 143– 56. 50 Hof RP. Comparison of cardiodepressant and vasodilator effects of PN200–110 (isradipine), nifedipine and diltiazem in anesthetized rabbits. Am J Cardiol 1987; 59(suppl): 37B– 42. 51 Hof RP. Interaction between two calcium antagonists and two beta blockers in conscious rabbits: hemodynamic consequences of differing cardiodepressant properties. Am J Cardiol 1987; 59(suppl): 43B– 51. 52 Hof RP, Evenou JP, Hof-Miyashita A. Similar increase in circulating renin after equihypotensive doses of nitroprusside, dihydralazine or isradipine in conscious rabbits. Eur J Pharmacol 1987; 136: 251– 4. 53 Hof RP, Hof A. Vasoconstrictor and vasodilator effects in normal and atherosclerotic conscious rabbits. Br J Pharmacol 1988; 95: 1075– 80. 54 Hof RP, Hof A. The renin-angiotensin system modulates the peripheral vascular effects of the calcium antagonist isradipine in anesthetized rabbits. J Cardiovasc Pharmacol 1988; 12: 233– 8. 55 Hof RP, Hof A, Scholtysik G, Menninger K. Effects of the new calcium antagonist PN200–110 on the myocardium and the regional peripheral circulation in anesthetized cats and dogs. J Cardiovasc Pharmacol 1984; 6: 407– 16. 56 Hof RP, Hof A, Takiguchi Y. Comparative haemodynamic studies of isradipine and dihydralazine in atherosclerotic and normal rabbits. J Cardiovasc Pharmacol 1990; 15(suppl 1): S13– 22. 57 Hof RP, Hof-Miyashita A. Different peripheral vasodilator effects of isradipine in sodium-loaded and sodium-depleted rabbits. Gen Pharmacol 1988; 19: 243– 7. 58 Hof RP, Rüegg UT. Pharmacology of the new calcium antagonist isradipine and its metabolites. Am J Med 1988; 84(suppl 3B): 13– 7. 59 Hof RP, Rüegg UT. Antivasoconstrictor effects of isradipine: a quantitative approach in anaesthetized rats and conscious rabbits. Am J Med 1989; 86(suppl 4A): 50– 6. 60 Hof RP, Rüegg UT. Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity. Am J Hypertens 1991; 4(suppl): 107S– 13. 61 Hof RP, Salzmann R, Siegl H. Selective effects of PN200–110 (isradipine) on the peripheral circulation and the heart. Am J Cardiol 1987; 59(suppl): 30B– 6. 62 Hof RP, Scholtysik G, Loutzenhiser R, Vuorela HJ, Neumann P. PN200–110, a new calcium antagonist: electrophysiological, inotropic and chronotropic effects on guinea-pig myocardial tissue and effects on contraction and calcium uptake of rabbit aorta. J Cardiovasc Pharmacol 1984; 6: 399– 406. 63 Hof RP, Tapparelli C, Weinstein DB. Hemodynamic, antivasoconstrictor, and antiatherosclerotic effects of calcium antagonists in animal models of atherosclerosis. J Cardiovasc Pharmacol 1990; 15(suppl 1): S7– 12. 64 Hof RP, Vuorela HJ. Assessing calcium antagonism on vascular smooth muscle: a comparison of three methods. J Pharmacol Methods 1983; 9: 41– 52. 65 Hoick M, Osterrieder W. Inhibition of myocardial Ca2+ channels by three dihydropyridines with different structural features: potential-dependent blockade by Ro 18-3981. Br J Pharmacol 1987; 91: 61– 7. 66 Holmes DG, Moullet Ch. Clinical equivalence of once-daily administration of a modified-release formulation of isradipine and twice-daily administration of the standard formulation. J Cardiovasc Pharmacol 1992; 19(suppl 3): S61– S65. 67 Holmes DG, Kutz K. Bioequivalence of a slow release formulation of isradipine and a non-retarded formulation. Am J Hypertens (in press). 68 Hoppeler H, Hess OM, Hug R, Turina J, Krayenbühl HP. Effect of isradipine on left ventricular relaxation and diastolic filling. J Cardiovasc Pharmacol 1990; 15(suppl 1): S79– 83. 69 The Isradipine in Hypertension Study Group. A multicentre evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension. Am J Med 1989; 86(suppl 4A): 119– 23. 70 The Italo-Belgian Isradipine Study Group. Multicentre evaluation of the safety and efficacy of isradipine in hypertension. Am J Med 1989; 86(suppl 4A): 94– 7. 71 Janis RA, Triggle DJ. New developments in Ca2+ channel antagonists. J Med Chem 1983; 26: 775– 84. 72 Katz A, Leach N. Differential effects of 1,4-dihydropyridine calcium channel blockers: therapeutic implications. J Clin Pharmacol 1987; 27: 825– 34. 73 Kirch W, Burger KJ, Weidinger G, Welzel D. Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension. J Cardiovasc Pharmacol 1990; 15(suppl 1): S55– 9. 74 Kirkendall WM. Comparative assessment of first-line agents for treatment of hypertension. Am J Med 1988; 84(suppl 3B): 32– 41. 75 Kjeldsen K, Stender S. Calcium antagonists and experimental atherosclerosis. Proc Soc Exp Biol Med 1989; 190: 219– 28. 76 Klauser R, Speiser P, Gisinger C, Schemthaner G, Prager R. Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus. J Cardiovasc Pharmacol 1990; 15(suppl 1): S93– 6. 77 Kokubun S, Prod'hom B, Becker C, Porzig H, Reuter H. Studies on Ca channels in intact cardiac cells: voltage-dependent effects and cooperative interactions of dihydropyridine enantiomers. Mol Pharmacol 1986; 30: 571– 84. 78 Krusell LR, Jespersen LT, Schmitz A, Thomsen K, Pedersen LO. Repetitive natriuresis and blood pressure. Long-term calcium entry blockade with isradipine. Hypertension 1987; 10: 577– 81. 79 Kruyssen HACM, Remme WJ, Knufmann KR, Battels GL. Acute haemodynamic effects of isradipine (Lomir) in patients with coronary artery disease and concomitant beta-blocking therapy. In: PA Zwieten, ed. Calcium antagonists—investigations with isradipine, International Congress and Symposium Series. London , New York : Royal Society of Medicine Services Ltd., 1988: 43– 56. 80 Lacourciere Y, Gagne C, Brun D, Poirier L, Dion D, Yardley C. Beneficial effects of the calcium antagonist isradipine on apolipoproteins in hypertensive patients. Am J Hypertens 1991; 4(suppl): 181S– 4. 81 Lacourciere Y, Poirier L, Dion D, Provencher P. Antihypertensive effect of isradipine administered once or twice daily on ambulatory blood pressure. Am J Cardiol 1990; 65: 467– 72. 82 Lagas M, Jonkmann JHG. Influence of food on the rate and extent of absorption of theophylline after single dose oral administration of controlled release tablet. Int J Clin Pharmacol Ther Toxicol 1985; 23: 424– 6. 83 Laplanche R, Fertil B, Nüesch E, Jais J-P, Niederberger W, Steimer J-L. Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine. Clin Pharmacol Ther 1991; 50: 39– 54. 84 Lawrence CJ, Lestrade A, De Lange S. Isradipine, a calcium antagonist, in the control of hypertension following coronary artery-bypass surgery. Am J Hypertens 1991; 4(suppl): 207S– 9. 85 Lee HR, Roeske WR, Yamamura HI. High affinity specific [3H](+)PN200–110 binding to dihydropyridine receptors associated with calcium channels in rat cerebral cortex and heart. Life Sci 1984; 35: 721– 32. 86 Low RI, Takeda P, Mason DT, DeMaria AN. The effects of calcium channel blocking agents on cardiovascular function. Am J Cardiol 1982; 49: 547– 53. 87 MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effect of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomised controlled trials. Prog Cardiovasc Dis 1986; 29(suppl 1): 99– 118. 88 Man in't Veld AJ, Holmes DG, Lasance A, de Zwart P. Isradipine twice daily lowers blood pressure over 24 hours. Am J Hypertens 1991; 4(suppl): 131S– 4. 89 Marangos PJ, Finkel MS, Verma A, Maturi MF, Patel J, Patterson RE. Adenosine uptake sites in dog heart and brain; interaction with calcium antagonists. Life Sci 1984; 35: 1109– 16. 90 Marre M, Misumi J, Raemsch KD, Corvol P, Menard J. Diuretic and natriuretic effects of nifedipine on isolated perfused rat kidneys. J Pharmacol Exp Ther 1982; 223: 263– 70. 91 Mauser M, Voelker W, Ickrath O, Karsch KR. Myocardial properties of the new dihydropyridine calcium antagonist isradipine compared to nifedipine with or without additional beta blockade in coronary artery disease. Am J Cardiol 1989; 63: 40– 4. 92 McGrath BP, Newmann R, Older P. Hemodynamic study of short- and long-term isradipine treatment in patients with chronic ischemic congestive heart failure. Am J Med 1989; 86(suppl 4A): 75– 80. 93 Messerli FH. “Cardioprotection”—not all calcium antagonists are created equal. Am J Cardiol 1990; 66: 855– 6. 94 Millard RW, Lathrop DA, Grupp G, Ashraf M, Grupp IL, Schwartz A. Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms. Am J Cardiol 1982; 49: 499– 506. 95 Mitchell LB, Schroeder JS, Mason JW. Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine: a review. Am J Cardiol 1982; 49: 629– 35. 96 Monhanty PK, Gonasun LM, Goodmann RP, et al. Isradipine (PN 200-110) versus hydrochlorothiazide in mild to moderate hypertension: a multicentre study. Am J Hypertens 1988; 1(suppl): 241S– 4. 97 Morel N, Godfraind T. Prolonged depolarization increases the pharmacological effect of dihydropyridines and their binding affinity for calcium channels of vascular smooth muscle. J Pharmacol Exp Ther 1987; 243: 711– 5. 98 Morel N, Godfraind T. Selective modulation by membrane potential of the interaction of some calcium entry blockers with calcium channels in rat mesenteric artery. Br J Pharmacol 1988; 95: 252– 8. 99 Morel N, Godfraind T. Pharmacological properties of voltage-dependent calcium channels in functional microvessels isolated from rat brain. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 442– 51. 100 Mosler KH. The treatment of threatened premature labour by tocolytics, Ca++-antagonist and anti-inflammatory drugs. Arzneimittelforschung 1975; 25: 263– 6. 101 Motomura S, Taira N. Differential effects of organic slow inward current inhibitors, verapamil and nifedipine, on rate of atrioventricular rhythm and supraventricular tachycardia in the canine isolated, blood-perfused AV node preparation. Naunyn Schmiedebergs Arch Pharmacol 1981; 315: 241– 8. 102 Müller-Schweinitzer E, Neumann P. In vitro effects of the calcium antagonists PN200-110, nifedipine, and nimodipine on human and canine cerebral arteries. J Cereb Blood Flow Metab 1983; 3: 354– 61. 103 Murphy KMM, Gould RJ, Largent BL, Snyder SH. A unitary mechanism of calcium antagonist drug action. Proc Natl Acad Sci USA 1983; 80: 860– 4. 104 Nayler WG, Poole-Wilson PA. Calcium antagonists: definition and mode of action. Basic Res Cardiol 1981; 76: 1– 15. 105 Nowycky MC, Fox AP, Tsien RW. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature (Lond) 1985; 316: 440– 3. 106 Pabst G, Jaeger H. Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol 1990; 38: 5– 10. 107 Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 1989; 80(suppl IV): IV-59– 67. 108 Packer M, Kessler PD, Lee WH. Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation 1987; 75(suppl V): V-56– 64. 109 Pedersen OL, Krusell LR, Sihm I, Jespersen LT, Thomsen K. Long-term effects of isradipine on blood pressure and renal function. Am J Med 1989; 86(suppl 4A): 15– 8. 110 Persson B, Andersson OK, Wysocki M, Hedner T, Aurell M. Renal and haemodynamic effects of isradipine in essential hypertension. Am J Med 1989; 86(suppl 4A): 60– 4. 111 Persson B, Wysocki M, Andersson OK. Long-term renal effects of isradipine, a calcium entry blocker, in essential hypertension. J Cardiovasc Pharmacol 1989; 14: 22– 4. 112 Pollare T, Lithell H, Berne Ch. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868– 73. 113 Rab SM, Mirza MA, Khan MH, Samad A, Ahmed M. Double-blind multicentre isradipine dose confirmation study in Pakistan. Drugs 1990; 40(suppl 2): 30– 2. 114 Reuter H. A variety of calcium channels. Nature (Lond) 1985; 316: 391. 115 Roberts SA, Nett TM, Hartman HA, Adams TE, Stoll RE. SDZ 200-110 induces Leydig cell tumours by increasing gonadotropin in rats. J Am Coll Toxicol 1989; 8: 487– 505. 116 Romey G, Garcia L, Rieger F, Lazdunski M. Targets for calcium channel blockers in mammalian skeletal muscle and their respective functions in excitation-contraction coupling. Biochem Biophys Res Commun 1988; 156: 1324– 32. 117 Rowe JW. Approach to the treatment of hypertension in older patients: preliminary results with isradipine. Am J Med 1988; 84(suppl 3B): 46– 50. 118 Rüegg PC, David D, Loria Y. Isradipine for the treatment of hypertension following coronary bypass graft surgery. A randomized trial versus sodium nitroprusside. Eur J Anaesthesiol (in press). 119 Sauter A, Rudin M. Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging. Stroke 1986; 17: 1228– 34. 120 Sauter A, Rudin M. Effects of calcium antagonists on high-energy phosphates in ischemic rat brain measured by 31P NMR spectroscopy. Magn Reson Med 1987; 4: 1– 8. 121 Sauter A, Rudin M. Treatment of hypertension with isradipine reduces infarct size following stroke in laboratory animals. Am J Med 1989; 86(suppl 4A): 130– 3. 122 Sauter A, Rudin M, Wiederhold KH, Hof RP. Cerebrovascular, biochemical and cytoprotective effects of isradipine in laboratory animals. Am J Med 1989; 86(suppl 4A): 134– 46. 123 Schmitz G, Hankowitz J, Kovacs EM. Cellular processes in atherogenesis: potential targets of Ca2+ channel blockers. Atherosclerosis 1991; 88: 109– 32. 124 Schran HF, Jaffe JM, Gonasun L. Clinical pharmacokinetics of isradipine. Am J Med 1988; 84(suppl 3B): 80– 9. 125 Shepherd AMM, Carr AA, Davidov M, et al. Efficacy and safety of isradipine in hypertension. J Cardiovasc Pharmacol 1989; 13: 580– 5. 126 Simonsen K, Sundstedt CD. Dose-response relationship and incidence of adverse drug reactions with isradipine in patients with essential hypertension. Am J Med 1989; 86(suppl 4A): 91– 3. 127 Soret Ph, Waeber B, Lüscher TF. Efficacy and tolerability of isradipine and sustained release nifedipine in the management of hypertension [Abstract]. Am J Hypertens 1990; 5: 119A. 128 Stein GH, Matthews K, Bannatyne RE, Quay G, Lopez L, McCarley D. Long-term lipid profiles with isradipine and hydrochlorothiazide treatment in elderly hypertensive patients. J Cardiovasc Pharmacol 1990; 15(suppl 1): S90– 2. 129 Striessnig J, Zernig G, Glossmann H. Human red-blood-cell Ca2+-antagonist binding sites. Evidence for an unusual receptor coupled to the nucleoside transporter. Eur J Biochem 1985; 150: 67– 77. 130 Sundstedt CD, Rüegg PC, Keller A, Waite R. A multicentre evaluation of the safety, tolerability and efficacy of isradipine in the treatment of essential hypertension. Am J Med 1989; 86(suppl 4A): 98– 102. 131 Taira N. Differences in cardiovascular profile among calcium antagonists. Am J Cardiol 1987; 59(suppl): 24B– 9. 132 Tanomsup S, Tantbirojn P, Koanantakul B, et al. Multicentre isradipine dose-confirmation study in Thai patients with hypertension. Drugs 1990; 40(suppl 2): 22– 5. 133 Trost BN, Weidmann P. Effect of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens 1987; 5(suppl 4): S81– 104. 134 Tse FLS, Jaffe JM. Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man. Eur J Clin Pharmacol 1987; 32: 361– 5. 135 Underwood SM, Davies SW, Feneck RO, Lunnon MW, Walesby RK. Comparison of isradipine with nitroprusside for control of blood pressure following myocardial revascularisation: effects on haemodynamics, cardiac metabolism, and coronary blood flow. J Cardiothorac Vase Anaesth 1991; 5: 348– 56. 136 Underwood SM, Feneck RO, Davies SW, Walesby RK, Lunnon MW. Use of isradipine in hypertension following coronary artery bypass surgery. Am J Med 1989; 86(suppl 4A): 81– 7. 137 Van Breemen D, Leijten P, Yamamoto H, Aaronson P, Cauvin C. Calcium activation of vascular smooth muscle: state of the art lecture. Hypertension 1986; 8(suppl II): II89– 95. 138 Van den Berg EK, Dehmer GJ. Acute haemodynamic effects of intravenous isradipine. Am J Cardiol 1988; 61: 1102– 5. 139 Van den Toren EW, Van Bruggen A, Rüegg PC, Lie KI. Haemodynamic effect of an intravenous infusion of isradipine in patients with congestive heart failure. Am J Med 1988; 84(suppl 3B): 97– 101. 140 Vater W, Kroneberg G, Hoffmeister F. Zur Pharmakologie von 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsauredimethylester (Nifedipine), BAY a 1040. Arzneimittelforschung 1972; 22: 1– 14. 141 Vermeulen A, Wester A, Willemse PFA, Lustermans FAT, Stegeman CJ, de Bruijn JHB. Comparison of isradipine and diltiazem in the treatment of essential hypertension. Am J Med 1988; 84(suppl 3B): 42– 5. 142 Wada Y, Satoh K, Taira N. A study on the separation of the coronary vasodilator from cardiac effects of PN200-110, a new dihydropyridine calcium antagonist, in the dog heart. J Cardiovasc Pharmacol 1985; 7: 190– 6. 143 Wagner K, Henkel M, Heinemeyer G, Neumayer H-H. Interaction of calcium blockers and cyclosporine. Transplant Proc 1988; 20(suppl 2): 561– 8. 144 Weinstein DB, Heider JG. Antiatherogenic properties of calcium antagonists. Am J Cardiol 1987; 59(suppl): 163B– 72. 145 Weinstein DB, Heider JG. Antiatherogenic properties of calcium antagonists: state of the art. Am J Med 1989; 86(suppl 4A): 27– 32. 146 Welzel D, Burger KJ. The calcium antagonist isradipine in the therapy of hypertension. A double-blind crossover comparison with nifedipine. Drugs 1990; 40(suppl 2): 60– 4. 147 Welzel D, Burger KJ, Weidinger G. Calcium antagonists as first-line antihypertensive agents: a placebocontrolled, comparative trial of isradipine and nifedipine. J Cardiovasc Pharmacol 1990; 15(suppl 1): S70– 4. 148 Wibo M, DeRoth L, Godfraind T. Pharmacologic relevance of dihydropyridine binding sites in membranes from rat aorta: kinetic and equilibrium studies. Circ Res 1988; 62: 91– 6. 149 Wittenberg C, Rosenfeld JB. Acute antihypertensive and renal effects of isradipine in hypertensive patients with normal and reduced renal function. Am J Hypertens 1991; 4(suppl): 191S– 3. 150 Zubair M, Karim S, Hussain S. Isradipine in Asian patients with hypertension. Drugs 1990; 40(suppl 2): 26– 9. Citing Literature Volume10, Issue1March 1992Pages 3-25 ReferencesRelatedInformation